REG - Oxford Biomedica PLC - Oxford Biomedica Agreement with Cabaletta Bio

Oxford BioMedicaAnnouncement

05/01/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220105:nRSE4280Xa&default-theme=true

RNS Number : 4280X  Oxford Biomedica PLC  05 January 2022

 

 

Oxford Biomedica Signs Licence and Supply Agreement with Cabaletta Bio for
LentiVector® Platform

Oxford, UK - 5 January 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford
Biomedica" or "the Group"), a leading gene and cell therapy group, today
announces that it has signed a new License and Supply Agreement (LSA) with
Cabaletta Bio, Inc. (Nasdaq: CABA) ("Cabaletta Bio"), a Philadelphia,
USA-based clinical-stage biotechnology company focused on the discovery and
development of engineered T cell therapies for patients with B cell-mediated
autoimmune diseases. The LSA grants Cabaletta Bio a non-exclusive license to
Oxford Biomedica"™s LentiVector® platform for its application in Cabaletta
Bio"™s leading Chimeric AutoAntibody Receptor (CAAR) T programme, DSG3-CAART
(targeting DSG3), and puts in place a multi-year Supply Agreement. The
financial arrangements of this LSA are in line with comparable deals the Group
has previously secured.

Cabaletta Bio"™s DSG3-CAART product candidate utilises Cabaletta"™s CAAR T
approach, in which the patient"™s own T cells are genetically engineered to
express the target autoantigen and direct them to recognise and eliminate the
pathogenic B cells. DSG3-CAART is being evaluated in the DesCAARTes™ Phase 1
clinical trial as a potential treatment for patients with mucosal pemphigus
vulgaris (mPV), a prototypical B cell-mediated autoimmune disease. The LSA
also allows for the parties to initiate additional projects in the future.

John Dawson, Chief Executive Officer of Oxford Biomedica, said: "Cabaletta
Bio is one of the leading companies developing engineered T cells designed to
treat patients with autoimmune diseases. We are delighted to announce this new
collaboration which strengthens our portfolio of relationships with leaders in
the gene-modified cell therapy field."

Gwendolyn Binder, Ph.D., EVP of Science and Technology, Cabaletta Bio, said:
"Oxford Biomedica"™s LentiVector® platform technology is well established
with regulators, and we are impressed by their continuous process
improvements, GMP manufacturing and validation expertise. We are very pleased
to be working with them to support the clinical and commercial development of
our DSG3-CAART program."

 

-Ends-

 

Enquiries:

 

Oxford Biomedica plc: T: +44 (0)1865 783 000 / E: ir@oxb.com

 

John Dawson, Chief Executive Officer

Stuart Paynter, Chief Financial Officer

Sophia Bolhassan, Head of Investor Relations

 

Consilium Strategic Communications: T: +44 (0)20 3709 5700

 

Mary-Jane Elliott / Matthew Neal

 

 

 

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell
therapy group focused on developing life changing treatments for serious
diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a
sector leading lentiviral vector delivery platform (LentiVector®), which the
Group leverages to develop in vivo and ex vivo products both in-house and with
partners. The Group has created a valuable proprietary portfolio of gene and
cell therapy product candidates in the areas of oncology, CNS disorders and
liver diseases. The Group has also entered into a number of partnerships,
including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard
Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim and Arcellx,
through which it has long-term economic interests in other potential gene and
cell therapy products. Additionally, the Group has signed a 3-year master
supply and development agreement with AstraZeneca for large-scale
manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222.
Oxford Biomedica is based across several locations in Oxfordshire, UK and
employs more than 740 people. Further information is available at www.oxb.com
(http://www.oxb.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRDZLFBLFLEBBF